1
|
Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, Hishizawa M, Kurose T, Deacon CF, Holst JJ, Hirano T, Inagaki N, Seino Y. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2014; 1:56-9. [PMID: 24843409 PMCID: PMC4020678 DOI: 10.1111/j.2040-1124.2010.00010.x] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Although glucose-dependent insulinotropic polypeptide (GIP) levels have been characterized previously, GLP-1 levels in Asians remain unclear. Here, we investigate total and intact levels of GLP-1, as well as GIP during oral glucose and meal tolerance tests (OGTT and MTT) in Japanese patients with or without type 2 diabetes (T2DM). Seventeen Japanese healthy controls and 18 age-matched and untreated patients with T2DM of short duration participated in the present study. Fasting levels of total GPL-1 were similar between the two groups (approximately 15 pM), and intact GLP-1 levels were considerably low in both groups (less than 1 pM). In both groups, total GLP-1 reached a peak 30 min after glucose ingestion (30-40 pM), whereas intact GLP-1 levels remained low with no significant peak. In MTT, total and intact GLP-1 showed no obvious peak. The current data indicate that intact GLP-1 levels are considerably low in the Japanese and that meal-induced enhancement of GLP-1 secretion is negligible in the Japanese. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00010.x, 2010).
Collapse
Affiliation(s)
- Daisuke Yabe
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| | - Akira Kuroe
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| | - Soushou Lee
- Department of Diabetes, Metabolism and Endocrinology, Showa University School of Medicine, Tokyo, Japan
| | - Koin Watanabe
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| | - Takanori Hyo
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| | - Masahiro Hishizawa
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| | - Takeshi Kurose
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| | - Carolyn F Deacon
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jens J Holst
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Tsutomu Hirano
- Department of Diabetes, Metabolism and Endocrinology, Showa University School of Medicine, Tokyo, Japan
| | - Nobuya Inagaki
- Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Yutaka Seino
- Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric Power Hospital, Osaka
| |
Collapse
|
2
|
Kume S, Uzu T, Takagi C, Kondo M, Okabe T, Araki SI, Isshiki K, Takeda N, Kondo K, Haneda M, Koya D, Nishio Y, Kashiwagi A, Maegawa H. Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis. J Diabetes Investig 2014; 3:298-301. [PMID: 24843580 PMCID: PMC4014953 DOI: 10.1111/j.2040-1124.2011.00169.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Anti-diabetic agent-related hypoglycemia is a serious complication in type 2 diabetic patients on hemodialysis. Therefore, we assessed the efficacy and tolerability of 24 weeks of monotherapy with vildagliptin, a dipeptidyl peptidase four inhibitor, which is a new class of antidiabetic agent. This open-label, single-arm clinical trial was performed on 26 patients on hemodialysis. The primary assessments were changes in postprandial glucose level and glycated albumin (GA). During the study, three patients dropped out, and data from 23 patients were analyzed. Significant reductions were seen in postprandial glucose (-2.60 ± 3.80 mmol/L, P < 0.001) and GA (-2.59 ± 2.33%, P < 0.001) levels. No serious drug-related adverse events were observed. Vildagliptin monotherapy can be recommended for glycemic control in type 2 diabetic patients on hemodialysis. This trial was registered with the University Hospital Medical Information Network (no. UMIN000003661). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00169.x, 2011).
Collapse
Affiliation(s)
- Shinji Kume
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Takashi Uzu
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | | | | | - Tomoko Okabe
- Rakuwakai Otowa Memorial Hospital, Yamashina, Kyoto
| | - Shin-Ichi Araki
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Keiji Isshiki
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Naoko Takeda
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Keiko Kondo
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Masakazu Haneda
- Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido
| | - Daisuke Koya
- Division of Diabetes & Endocrinology, Kanazawa Medical University, Kahoku-Gun, Ishikawa, Japan
| | - Yoshihiko Nishio
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Atsunori Kashiwagi
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| | - Hiroshi Maegawa
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga
| |
Collapse
|